Beigene Ltd (BGNE) Stock Price Down 1.2%
Shares of Beigene Ltd (NASDAQ:BGNE) were down 1.2% during trading on Tuesday . The stock traded as low as $28.96 and last traded at $29.71, with a volume of 56,522 shares changing hands. The stock had previously closed at $30.06.
Several analysts recently commented on BGNE shares. Morgan Stanley upped their target price on Beigene from $39.00 to $42.00 in a report on Friday, April 8th. Cowen and Company restated an “outperform” rating on shares of Beigene in a report on Thursday, March 31st. Finally, Zacks Investment Research cut Beigene from a “hold” rating to a “sell” rating in a report on Monday, May 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $39.67.
The stock has a 50-day moving average price of $29.84 and a 200-day moving average price of $28.97. The firm’s market cap is $667.23 million.
Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.92. The firm earned $0.70 million during the quarter. The company’s quarterly revenue was down 50.0% compared to the same quarter last year. On average, equities analysts anticipate that Beigene Ltd will post ($3.17) earnings per share for the current fiscal year.
BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.